SGLT2 저해제/metformin 고정용량복합제의 국내 사용 현황Use of SGLT2 inhibitor/metformin fixed dose combination in Korea
- Authors
- 최하은; 이지원; 제남경; 정경혜
- Issue Date
- Mar-2022
- Publisher
- 한국임상약학회
- Keywords
- Type 2 diabetes; sodium glucose cotransporter-2 inhibitor; SGLT2i/metformin fixed-dose combination; two-pill combination
- Citation
- 한국임상약학회지, v.32, no.1, pp 13 - 19
- Pages
- 7
- Journal Title
- 한국임상약학회지
- Volume
- 32
- Number
- 1
- Start Page
- 13
- End Page
- 19
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/57751
- DOI
- 10.24304/kjcp.2022.32.1.13
- ISSN
- 1226-6051
2508-786X
- Abstract
- Background: The use of combination therapy and fixed-dose combination therapy is increasing for the treatment of type 2 diabetes. Sodium glucose cotransporter-2 inhibitor (SGLT2i) is a drug class used in combination with metformin. Methods: Type 2 diabetes patients on SGLT2i/metformin combination therapy were extracted from the 2019 Health Insurance Review & Assessment ServiceNational Patients Sample. On July 1, 2019, SGLT2i and metformin fixed-dose combination (SGLT2i/metformin FDC) and two-pill combination (TPC) groups were identified, and a chi-square test and multiple logistic regression were performed. Results: Of total 2,992 patients, 1,077 (36%) were prescribed SGLT2i/metformin FDC and 1,915 (64%) were prescribed TPC. We found that the most common comorbidities were in the order of dyslipidemia, gastrointestinal disease, and hypertension. Multiple logistic regression analysis showed that the use of SGLT2i/metformin FDC was lower than TPC in patients with diabetic neuropathy (OR=0.76, p=0.008). Clinic (OR=2.09, p
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/57751)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.